Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday

Design Therapeutics (NASDAQ:DSGN) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 12:30 PM ET.

Design Therapeutics Stock Down 2.2%

Shares of NASDAQ DSGN opened at $10.44 on Monday. The business’s 50 day moving average is $9.92 and its two-hundred day moving average is $8.02. Design Therapeutics has a 52-week low of $2.60 and a 52-week high of $11.14. The firm has a market cap of $594.66 million, a price-to-earnings ratio of -8.77 and a beta of 1.63.

Wall Street Analyst Weigh In

DSGN has been the subject of a number of research analyst reports. Craig Hallum assumed coverage on Design Therapeutics in a report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Design Therapeutics in a research report on Wednesday, January 21st. Oppenheimer initiated coverage on shares of Design Therapeutics in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $18.00 price objective for the company. Wall Street Zen raised shares of Design Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Leerink Partners set a $14.00 target price on shares of Design Therapeutics and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Design Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $15.00.

Institutional Investors Weigh In On Design Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vivo Capital LLC purchased a new stake in shares of Design Therapeutics during the 4th quarter worth $15,129,000. RA Capital Management L.P. lifted its holdings in Design Therapeutics by 207.2% during the 4th quarter. RA Capital Management L.P. now owns 1,461,381 shares of the company’s stock worth $13,708,000 after buying an additional 985,682 shares during the last quarter. Woodline Partners LP purchased a new stake in Design Therapeutics during the 1st quarter worth about $2,492,000. Invesco Ltd. boosted its position in shares of Design Therapeutics by 1,995.8% during the 4th quarter. Invesco Ltd. now owns 305,757 shares of the company’s stock worth $2,868,000 after acquiring an additional 291,168 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Design Therapeutics in the 4th quarter valued at about $2,115,000. 56.64% of the stock is currently owned by institutional investors and hedge funds.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.